The split ends a decades-long partnership that appeared to unravel after Lilly signed a deal earlier this year with Boehringer Ingelheim to jointly develop and sell several diabetes compounds that are in mid- and late-stage development, including a Boehringer oral diabetes agent known as linagliptin.